ID: ALA5218621

Max Phase: Preclinical

Molecular Formula: C20H17F3N2O4

Molecular Weight: 406.36

Representations

Canonical SMILES:  COc1cc(C)c(-n2c(=O)cc(C(F)(F)F)[nH]c2=O)cc1Oc1ccccc1C

Standard InChI:  InChI=1S/C20H17F3N2O4/c1-11-6-4-5-7-14(11)29-16-9-13(12(2)8-15(16)28-3)25-18(26)10-17(20(21,22)23)24-19(25)27/h4-10H,1-3H3,(H,24,27)

Standard InChI Key:  UCZYDAVGIKGBAO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 406.36

Molecular Weight (Monoisotopic): 406.1140

AlogP: 3.96

#Rotatable Bonds: 4

Polar Surface Area: 73.32

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.05

CX Basic pKa:

CX LogP: 4.20

CX LogD: 4.19

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.71

Np Likeness Score: -0.75

References

1. Günther J, Hillig RC, Zimmermann K, Kaulfuss S, Lemos C, Nguyen D, Rehwinkel H, Habgood M, Lechner C, Neuhaus R, Ganzer U, Drewes M, Chai J, Bouché L..  (2022)  BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe.,  65  (21.0): [PMID:36261130] [10.1021/acs.jmedchem.2c00441]

Source

Source(1):

• Scientific Literature